Coronavirus Disease 19 (COVID-19) in a Patient with Chronic HCV While on Direct-Acting Antiviral Therapy with a Worse Prognosis
Nahed A. Makhlouf, Hoda A. Makhlouf, Aliae A. R. Mohamed- Hussein, Ehab F. Moustafa, Amal A. Mahmoud, Sahar M. Hassany
Asian Journal of Research and Reports in Gastroenterology · pp. 120–124 · Published 7 Aug 2020
Abstract
Introduction: The world is suffering a major global health pandemic caused by a new strain of the coronavirus (COVID-19). Herein, we encountered one case with COVID-19 and chronic HCV while on Direct Acting Antiviral Therapy. Case Presentation: A 58-year male patient had chronic hepatitis C (HCV) without liver cirrhosis. He was on Direct - Acting Antiviral Therapy for HCV (DAAs) in the form of Sofosbuvir 400 mg daily and Daclatasvir 60 mg daily (on his third month). The patient developed acute respiratory symptoms suggestive of pneumonia. Oropharyngeal swab for COVID-19 was positive as detected by real-time polymerase-chain-reaction (PCR) assay. The treatment for COVID-19 was given according to the Ministry of Health Protocol in addition to oxygen therapy with the continuation of his anti HCV therapy. His symptoms and oxygen saturation progressively deteriorated. The patient died despite supportive measures. Conclusion: Clinicians should suspect a worse prognosis of COVID-19 in chronic HCV patient despite supportive therapy for COVID -19. The efficacy of Anti HCV therapy as protective or therapy against COVID-19 needs clinical trials.
Cited by 0
No indexed citations yet.
Related research
- Seroprevalence of HIV, HBV and HCV among Prisoners in Sokoto, Nigeria — shares topic coverage
- Evaluation of CD4 T Lymphocyte Cell Levels among Hepatitis B, C and E Viruses Negative Individuals in Ibadan, Southwestern Nigeria — shares topic coverage
- Anti-thyroid Antibodies in Patients with HCV Genotype 3a: A Pilot Study — shares topic coverage
- Hepatitis C Virus Infection among Chronic Renal Failure Patients Pre – Dialysis Therapy in Hodiedah City, Yemen — shares topic coverage
- Evaluation of Saliva as an Alternative Specimen to Serum for Diagnosis of Hepatitis C Virus Infection — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.